NCT02892734View on ClinicalTrials.gov

Ipilimumab and Nivolumab in Treating Patients With Recurrent Stage IV HER2 Negative Inflammatory Breast Cancer

PHASE2TerminatedINTERVENTIONAL
Enrollment

3

Participants

Timeline

Start Date

September 18, 2017

Primary Completion Date

February 4, 2019

Study Completion Date

February 4, 2019

Conditions
HER2/Neu NegativeRecurrent Inflammatory Breast CarcinomaStage IV Breast CancerStage IV Inflammatory Breast Carcinoma
Interventions
BIOLOGICAL

Ipilimumab

Given IV

OTHER

Laboratory Biomarker Analysis

Correlative studies

BIOLOGICAL

Nivolumab

Given IV

Trial Locations (1)

60611

Northwestern University, Chicago

Sponsors

Collaborators (1)

Bristol-Myers Squibb
All Listed Sponsors
collaborator

Bristol-Myers Squibb

INDUSTRY

collaborator

National Cancer Institute (NCI)

NIH

lead

Northwestern University

OTHER